Bydureon, the once-weekly diabetes treatment developed by Lilly, Amylin and Alkermes, has received marketing authorization in Europe. The marketing submission was built upon six years of market experience with Bydureon’s precursor, Byetta injection, the twice-daily form of exenatide that was developed by Lilly and Amylin. Bydureon is delivered using a biodegradable microsphere technology developed by Alkermes. A glucagon-like peptide-1 (GLP-1) receptor agonist, Bydureon is the first once-...